Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Novo Nordisk lowered its full-year guidance and named a new CEO. The pharma giant's shares plunged in early trades.

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

These big pharma stocks arguably aren't receiving the respect they deserve.

Wall Street might be underestimating these companies' potential.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market.

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims.

The Caviar Cruise stock screener identifies top long-term investments like Novo Nordisk (NVO), with strong revenue growth, high ROIC, solid cash flow, and pricing power—ideal for quality investors.

NOVO-NORDISK (NYSE:NVO) appears undervalued with strong profitability, solid growth, and a reasonable valuation, making it a potential candidate for value investors in the healthcare sector.

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector.

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

An update on Sana Biotechnology.